These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 26327487)

  • 1. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust.
    Giesinger JM; Kieffer JM; Fayers PM; Groenvold M; Petersen MA; Scott NW; Sprangers MA; Velikova G; Aaronson NK;
    J Clin Epidemiol; 2016 Jan; 69():79-88. PubMed ID: 26327487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Summary Score in Patients With Hematologic Malignancies.
    Efficace F; Cottone F; Sommer K; Kieffer J; Aaronson N; Fayers P; Groenvold M; Caocci G; Lo Coco F; Gaidano G; Niscola P; Baccarani M; Rosti G; Venditti A; Angelucci E; Fazi P; Vignetti M; Giesinger J
    Value Health; 2019 Nov; 22(11):1303-1310. PubMed ID: 31708068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.
    Husson O; de Rooij BH; Kieffer J; Oerlemans S; Mols F; Aaronson NK; van der Graaf WTA; van de Poll-Franse LV
    Oncologist; 2020 Apr; 25(4):e722-e732. PubMed ID: 32297435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer.
    Petersen MA; Aaronson NK; Conroy T; Costantini A; Giesinger JM; Hammerlid E; Holzner B; Johnson CD; Kieffer JM; van Leeuwen M; Nolte S; Ramage JK; Tomaszewski KA; Waldmann A; Young T; Zotti P; Groenvold M;
    Qual Life Res; 2020 May; 29(5):1405-1417. PubMed ID: 31955374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States.
    Nolte S; Liegl G; Petersen MA; Aaronson NK; Costantini A; Fayers PM; Groenvold M; Holzner B; Johnson CD; Kemmler G; Tomaszewski KA; Waldmann A; Young TE; Rose M;
    Eur J Cancer; 2019 Jan; 107():153-163. PubMed ID: 30576971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies.
    Sommer K; Cottone F; Aaronson NK; Fayers P; Fazi P; Rosti G; Angelucci E; Gaidano G; Venditti A; Voso MT; Baccarani M; Vignetti M; Efficace F
    Qual Life Res; 2020 Mar; 29(3):815-823. PubMed ID: 31782016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
    Park KU
    Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EORTC QLQ-C30 general population normative data for Italy by sex, age and health condition: an analysis of 1,036 individuals.
    Pilz MJ; Gamper EM; Efficace F; Arraras JI; Nolte S; Liegl G; Rose M; Giesinger JM;
    BMC Public Health; 2022 May; 22(1):1040. PubMed ID: 35610611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Azeri Version of European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30): Translation and Validation.
    Davudov MM; Harirchi I; Amiraliyev N; Mehtiyeva E; Mirzajani Z; Amiraliyev K; Rustamli N; Zebardast J; Montazeri A
    Asian Pac J Cancer Prev; 2020 Jan; 21(1):267-271. PubMed ID: 31983195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer.
    Musoro JZ; Coens C; Greimel E; King MT; Sprangers MAG; Nordin A; van Dorst EBL; Groenvold M; Cocks K; Velikova G; Flechtner HH; Bottomley A;
    Gynecol Oncol; 2020 Nov; 159(2):515-521. PubMed ID: 32972782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric properties of the EORTC QLQ-C30 in Uganda.
    Naamala A; Eriksson LE; Orem J; Nalwadda GK; Kabir ZN; Wettergren L
    Health Qual Life Outcomes; 2021 Apr; 19(1):131. PubMed ID: 33892718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26.
    Sztankay M; Aaronson NK; Arraras JI; Basso U; Bumbasirevic U; Efficace F; Giesinger JM; Johnson CD; van Leeuwen M; Oberguggenberger AS; Sosnowski R; Young T; Holzner B;
    BMC Cancer; 2018 Nov; 18(1):1104. PubMed ID: 30419889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.
    Petersen MA; Aaronson NK; Arraras JI; Chie WC; Conroy T; Costantini A; Dirven L; Fayers P; Gamper EM; Giesinger JM; Habets EJJ; Hammerlid E; Helbostad J; Hjermstad MJ; Holzner B; Johnson C; Kemmler G; King MT; Kaasa S; Loge JH; Reijneveld JC; Singer S; Taphoorn MJB; Thamsborg LH; Tomaszewski KA; Velikova G; Verdonck-de Leeuw IM; Young T; Groenvold M;
    Eur J Cancer; 2018 Sep; 100():8-16. PubMed ID: 29936066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Underlying dimensions of the EORTC QLQ-C30 in a Cuban population of patients with advanced non-small cell lung cancer.
    Viada C; Bouza C; Fors M; Frías A; Alvarez M; García L; Wilkinson B; Rodríguez C; Crombet T; Ballesteros J
    Qual Life Res; 2020 Dec; 29(12):3441-3448. PubMed ID: 33136243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs.
    Snyder CF; Blackford AL; Sussman J; Bainbridge D; Howell D; Seow HY; Carducci MA; Wu AW
    Qual Life Res; 2015 May; 24(5):1207-16. PubMed ID: 25398495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychometric validation of the Moroccan version of the EORTC QLQ-C30 in colorectal Cancer patients: cross-sectional study and systematic literature review.
    El Alami Y; Essangri H; Majbar MA; Boutayeb S; Benamr S; El Malki HO; Souadka A
    BMC Cancer; 2021 Jan; 21(1):99. PubMed ID: 33499819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conceptual structure of the Taiwan Chinese version of the EORTC QLQ-C30.
    Huang CC; Tu SH; Lien HH; Huang CS; Wang PC; Chie WC
    Qual Life Res; 2015 Aug; 24(8):1999-2013. PubMed ID: 25560775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normative data for the EORTC QLQ-C30 from the Austrian general population.
    Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B;
    Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors.
    Knobel H; Loge JH; Brenne E; Fayers P; Hjermstad MJ; Kaasa S
    Palliat Med; 2003 Dec; 17(8):664-72. PubMed ID: 14694917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing the measurement invariance of the EORTC QLQ-C30 across primary cancer sites using multi-group confirmatory factor analysis.
    Costa DS; Aaronson NK; Fayers PM; Pallant JF; Velikova G; King MT
    Qual Life Res; 2015 Jan; 24(1):125-33. PubMed ID: 25193618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.